Heart failure drug trial offers continued access for patients

NCT ID NCT07436689

ENROLLING_BY_INVITATION Disease control Sponsor: Tenax Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 02, 2026 · Last updated May 14, 2026 · Updated 9 times

Summary

This study gives people with pulmonary hypertension and heart failure continued access to an oral medication called levosimendan (TNX-103). It aims to track the safety of long-term use in 800 participants who previously received the drug in an earlier study. The main focus is monitoring side effects rather than testing new benefits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH HFPEF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Tenax Investigational Site

Chicago, Illinois, 60611, United States
Tenax Investigational Site

Minneapolis, Minnesota, 55455, United States
Tenax Investigational Site

Rochester, Minnesota, 55905, United States
Tenax Investigational Site

St Louis, Missouri, 63136, United States
Tenax Investigational Site

Charleston, South Carolina, 29425, United States

Conditions

Explore the condition pages connected to this study.

PULMONARY HYPERTENSION ASSOCIATED WITH HFPEF